MA46058A - Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles - Google Patents

Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles

Info

Publication number
MA46058A
MA46058A MA046058A MA46058A MA46058A MA 46058 A MA46058 A MA 46058A MA 046058 A MA046058 A MA 046058A MA 46058 A MA46058 A MA 46058A MA 46058 A MA46058 A MA 46058A
Authority
MA
Morocco
Prior art keywords
chylomicrons
proteins
nucleic acids
cholesteryl ester
body cells
Prior art date
Application number
MA046058A
Other languages
English (en)
Inventor
Mary P Mccourt
Lawrence Mielnicki
Jerome J Schentag
Original Assignee
Mary P Mccourt
Lawrence Mielnicki
Jerome J Schentag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mary P Mccourt, Lawrence Mielnicki, Jerome J Schentag filed Critical Mary P Mccourt
Publication of MA46058A publication Critical patent/MA46058A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA046058A 2016-08-23 2017-08-23 Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles MA46058A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662378599P 2016-08-23 2016-08-23

Publications (1)

Publication Number Publication Date
MA46058A true MA46058A (fr) 2019-07-03

Family

ID=61245234

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046058A MA46058A (fr) 2016-08-23 2017-08-23 Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles

Country Status (7)

Country Link
US (2) US20190175515A1 (fr)
EP (1) EP3503876A4 (fr)
JP (1) JP2019528294A (fr)
CN (1) CN110418636A (fr)
AU (1) AU2017315321A1 (fr)
MA (1) MA46058A (fr)
WO (1) WO2018039303A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119782B2 (en) 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
CN105164143B (zh) 2013-03-14 2019-02-19 杰罗米.J.申塔格 用于将分子引入到乳糜微粒中的胆固醇体囊泡
BR112019015797A2 (pt) 2017-02-01 2020-03-17 Modernatx, Inc. Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
CN115369091B (zh) * 2022-09-29 2023-07-28 成都赛诺联创生物科技有限公司 一种Caco-2细胞倒置模型及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US9119782B2 (en) * 2006-03-20 2015-09-01 Mary P. McCourt Drug delivery means
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
CN109172816A (zh) * 2012-03-29 2019-01-11 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
CN105164143B (zh) * 2013-03-14 2019-02-19 杰罗米.J.申塔格 用于将分子引入到乳糜微粒中的胆固醇体囊泡
WO2016155809A1 (fr) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Formulations de particules lipidiques permettant la délivrance à une cellule cible d'arn et de composés hydrosolubles thérapeutiquement efficaces

Also Published As

Publication number Publication date
CN110418636A (zh) 2019-11-05
EP3503876A4 (fr) 2020-06-10
US20190175515A1 (en) 2019-06-13
EP3503876A1 (fr) 2019-07-03
WO2018039303A1 (fr) 2018-03-01
JP2019528294A (ja) 2019-10-10
US20230240997A1 (en) 2023-08-03
AU2017315321A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
MA46058A (fr) Vésicules d'ester de cholestéryle chargeant des peptides, des protéines et des acides nucléiques dans des chylomicrons et des cellules corporelles
IL266045A (en) Proteins change from secretable immunomodulators and transgenic cell therapy
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
WO2017024317A3 (fr) Procédés pour induire la dégradation de protéine ciblée par des molécules bifonctionnelles
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
WO2017058892A3 (fr) Procédés et compositions pour vecteurs viraux évitant les anticorps
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
SG10201710631RA (en) Artificial nucleic acid molecules for improved protein or peptide expression
EP3498844A4 (fr) Complexe d'acide nucléique peptidique présentant une perméabilité cellulaire améliorée et composition pharmaceutique comprenant ce dernier
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
CO7020851A2 (es) Proteínas y péptidos modificados
IL269643A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus proteins and their use
BR112014020694A2 (pt) proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a
EP4085130A4 (fr) Administration transitoire basée sur la température d'acides nucléiques et de protéines à des cellules et des tissus
MX2016015594A (es) Productos farmaceuticos mejorados de peptido para resistencia a la insulina.
DK2858664T3 (da) Hgh-xten-fusionsprotein og anvendelse deraf i behandling af væksthormonmangel
EP3180463A4 (fr) Détection de protéines résiduelles de cellule hôte dans des préparations de protéines de recombinaison
PL2858490T3 (pl) Rekombinowane elementy dna do ekspresji rekombinowanych białek w owadach
EP3708661A4 (fr) Protéine de fusion d'enzyme thérapeutique à nouvelle structure et son utilisation
EA201790178A1 (ru) Пептиды, несущие маннозо-6-фосфат, слитые с лизосомальным ферментом
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
ES2970246T3 (es) Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
WO2014082042A3 (fr) Peptides qui stimulent l'adipogenèse sous-cutanée
EA201591796A1 (ru) Антитела к cd52
EP3362048A4 (fr) Composition destinée à une administration intra-orale de peptides et de protéines biologiquement actifs